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What you need to know
• “Triage” blood tests in primary care, such as haemoglobin, platelets,
serum calcium level, liver function tests, and inflammatory markers such
as C reactive protein and erythrocyte sedimentation rate may provide
“clues” to cancer in patients with non-specific symptoms
• Triage tests do not have the performance characteristics of rule-out
tests
• Evidence supports the use of only a small number of specific cancer
markers, such as CA125 and PSA, in primary care
A 61 year old man with a one month history of back pain visits
his general practitioner (GP). He has hypertension, has never
smoked, and reports fatigue for several months. The pain is
keeping him awake at night. He has not lost weight. Clinical
examination is normal. The differential diagnosis for this patient
is wide, including potential malignant causes such as pancreatic,
myeloma, and prostate cancer or metastatic disease.
Cancer can be difficult to identify, as many of the common
symptoms are non-specific and low risk, and even the most well
known “alarm” symptoms have relatively low positive predictive
values (PPVs) for underlying malignancy.1 For example, weight
loss has a PPV for underlying malignancy of only 0-3.3%,2
while rectal bleeding has a PPV of 2.2-15.8%.3 Cancer markers
used in hospital settings, when applied to low risk primary care
patients, have low positive predictive values and high false
positive rates.4 Identifying patients whose non-specific
symptoms may be caused by cancer, rather than benign disease,
is therefore a challenge for primary care physicians.
While formal diagnosis usually happens in secondary care, the
first suspicion of cancer generally occurs in primary care.
Patients whose symptoms represent an approximate risk of
cancer of ≥3% are recommended by the National Institute for
Health and Care Excellence (NICE) for urgent investigation,
often by referral.5 Those with estimated risk <3% may receive
an initial panel of primary care investigations, or triage testing,
to stratify risk. Triage tests can provide clues to help identify
patients for referral, and crucially can point towards the site of
an underlying malignancy. This is particularly useful when the
patient’s vague symptoms could be caused by several different
cancer types, and can guide decision making on any need for
further investigation.
This article discusses blood tests to detect or stratify risk for
possible cancer in primary care and presents evidence for their
use in symptomatic patients. First we consider tests that are not
specific for any one type of cancer but which may help primary
care providers stratify risk of malignancy. Then we discuss
specific markers for certain types of cancer. Blood tests that
might be used for screening asymptomatic patients, tests for
less common malignancies (eg, gastrin, prolactin) or for
monitoring patients with known malignancies, are beyond the
scope of this article.
Search strategy
In August 2019 we replicated the search strategy used by NICE in its most
recent guidance, NG12, restricted to papers published after 2014 (2011 for
ovary) as the NICE searches had been performed before that date. LM, SB,
and WH worked in pairs to assess candidate abstracts for blood tests used
in primary care, and extracted full texts for relevant hits, supplemented by a
large personal library of existing references.
What is the next investigation?
Non-specific blood tests or clues for cancer
Several non-specific tests, commonly used in primary care, can
provide “clues” towards possible cancer. Tests with a PPV for
cancer of >1%, including haemoglobin, platelet count, serum
calcium, liver function tests, and inflammatory markers such
as C reactive protein (CRP) and erythrocyte sedimentation rate
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(ESR), are summarised in fig 1 (infographic). Tests with PPVs
<1% for certain underlying malignancies are reported in the
same graphic. These blood tests should not be measured
routinely but should be considered in patients with low risk, but
not no risk symptoms, such as unexplained weight loss or
persistent tiredness. Rarely, the full blood count may identify
a haematological cancer, but most tests act in a bayesian fashion,
whereby a “positive test” makes cancer a more likely
explanation.
Although non-cancer diagnoses can also commonly cause
abnormal test results, further investigations or referral to rule
out malignancy may be warranted. Conversely, a “negative”
test makes cancer less likely, though neither result is definitive;
that is, if these test results are normal, cancer may still be
present.6 None of these tests has sufficient sensitivity to act as
a “rule out” test, with the possible exception of the combination
of a normal plasma viscosity or ESR plus normal full blood
count, which may be used as a simple rule out for myeloma.7
In the context of low risk symptoms, negative tests provide
some reassurance. However, if symptoms continue or change,
further investigation may still be warranted. Ideally, the rationale
for and implications of a negative or positive test result should
be discussed before ordering these tests so as to allow for shared
decision making with patients.
Specific cancer markers
Despite the proliferation of cancer biomarker research in
secondary care, there is a shortage of relevant primary care
studies, with no new markers entering primary care usage since
Sturgeon et al’s review in 2009.8 The small number of cancer
specific tests validated for diagnosis of cancer in primary care
settings are summarised in table 1. These tests should be used
in symptomatic patients, rather than as a non-specific cancer
screen. Even well known cancer markers that are part of routine
clinical practice, such as prostate specific antigen (PSA) and
cancer antigen 125 (CA125), have a limited primary care
evidence base. In the case of PSA, because so many men who
develop prostate cancer will be asymptomatic,11 positive
predictive value of a positive test does not necessarily translate
into clinical benefit.
Outcome
The general practitioner was concerned by the presence of night
pain and fatigue, which, in combination with the patient’s age,
raised the possibility of underlying malignancy. The patient was
therefore referred for initial blood tests, which included a full
blood count, liver function tests, serum calcium, and ESR.
Results were significant for a slightly raised platelet count
(495×109/L) and a moderately raised ESR (34 mm/h). Further
specific blood tests were therefore performed, including serum
electrophoresis and Bence Jones protein. Monoclonal
immunoglobulins were detected, suggestive of multiple
myeloma. The patient was referred urgently to a suspected
cancer clinic, where the diagnosis was confirmed.
Future research
Many cancer biomarkers are being investigated, particularly for
cancers considered “hard to diagnose,” such as pancreas and
ovary,12 or for early detection of cancer recurrences.9 However,
of the candidate cancer biomarkers, few are expected to be tested
for in clinical practice.13 Future research to evaluate markers
for a potential diagnostic role should aim to quantify the
false-positive rates, clinician and patient acceptability, and health
economic aspects in order to determine how these tests should
best be used.
How patients were involved in the creation of this article
A first patient contributor was involved in the early stages of the article but
was unavailable during the main creation of the piece. SC joined at that stage,
and has helped interpret our findings, especially the patient aspects, and in
critical review of the whole manuscript, ensuring it remained patient centred.
Contributors LM performed the searches, LM, SB, and WH reviewed abstracts and
extracted full texts. JW, WH, and SB wrote the first draft of the article with input
from LM and SC. All authors contributed to the intellectual content, edited the
manuscript and approved the final version for submission.
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Table
Table 1| Specific blood tests for diagnosing cancer in symptomatic patients in primary care settings
When to consider testPositive predictive values (95%
confidence interval)
Available evidenceTestTarget cancer
Women with persistent abdominal distension,
feeling full, loss of appetite, pelvic/abdominal
pain, urgency or frequency (especially if aged
>50) 5
10.5% (5.6 to 15.4)Cohort study: 4379 women with primary
care CA125 results; 152 with newly raised
CA125  >35u/mL and follow-up data.
Sixteen incident ovarian cancers
diagnosed9
CA125Ovarian cancer
In patients with symptoms of possible
myeloma, plus either a raised inflammatory
marker or a raised calcium
No primary care evidence foundSerum protein
electrophoresis
Myeloma
Men with lower urinary tract symptoms,
erectile dysfunction or haematuria 5
PSA <3ng/ml: <1%
3 ≤PSA <4: 1%
4 ≤PSA <6: 6%
6 ≤PSA <10: 18%
PSA ≥10: 45%*
Cohort study: 120 697 men aged ≥45
years with PSA results; 7538 incidence
prostate cancers diagnosed 10
PSAProstate cancer
Currently not recommended in primary care
by NICE
No/minimal primary care evidence could be foundAFPLiver
CEAColorectal
CA19-9Pancreatic
* confidence intervals not reported. CA125=cancer antigen 125. PSA=prostate specific antigen
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Figure
Fig 1 Primary care studies or review investigating the diagnostic role of blood tests as non-specific cancer markers: with
positive predictive values (PPVs) ≥1% and <1%
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